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Abstract
Inorganic arsenic (iAs) exposure increases risk of several diseases, including cancer. Some 
nutrients such as flavonoids enhance glutathione activity, which in turn play a key role in iAs 
elimination. Our objective was to explore whether dietary non-soy flavonoids are associated with 
iAs metabolism. We hypothesized that the intake of flavonoids belonging to the following groups, 
flavan-3-ols, flavone, flavonol, flavanone, and anthocyanidin, is positively associated with urinary 
dimethylarsinic acid (DMA), which is the most soluble iAs metabolite excreted. We performed a 
cross-sectional study that included 1027 women living in an arsenic-contaminated area of northern 
Mexico. Flavonoid intake was estimated using a validated food frequency questionnaire. 
Concentration of urinary iAs and its metabolites (monomethylarsonic acid and DMA) were 
determined by high performance liquid chromatography ICP-MS. Results showed positive 
significant associations between DMA and the flavonoid groups flava-3-ols (β= 0.0112) and 
flavones (β= 0.0144), as well as the individual intake of apigenin (β= 0.0115), luteolin (β= 
0.0138), and eriodictyol (β= 0.0026). Our findings suggest that certain non-soy flavonoids may 
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improve iAs elimination; however, there is still very limited information available regarding the 
consumption of flavonoids and iAs metabolism.
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1. Introduction
Inorganic arsenic (iAs) is a metalloid naturally present in geological strata and contaminates 
drinking water sources in several areas of the world, including Argentina, Bangladesh, Chile, 
and Mexico. Cancer, development deficits, skin lesions, and diabetes, as well as respiratory, 
immunological, cardiovascular, and endocrine impairments are associated with iAs exposure 
[1].
Ingested iAs is biomethylated in the liver and eliminated primarily through urine. It is first 
reduced by glutathione (GSH) from its pentavalent (AsV) to its trivalent form (AsIII), then 
followed by oxidative methylation to form monomethylarsonic acid (MMAV) using S-
adenosyl methionine (SAM). This reduction and methylation process is repeated to form 
dimethylarsinic acid (DMAV), the most hydrophilic metabolite. Proportions of iAs (0.20 to 
0.25), MMA (0.15 to 0.25) and DMA (0.40 to 0.75) are found in urine. An increased 
proportion of MMA has been associated with arsenic-related disease risk [2]. Genetic, 
environmental, and dietary factors may contribute to the wide inter-individual variation in 
iAs elimination reported in the literature [3].
Flavonoids are a large group of natural polyphenolic compounds that are mainly derived 
from fruits and vegetables, which contributes to their color and flavor. There are six primary 
groups of flavonoids: flavan-3-ols, flavone, flavonol, flavanone, anthocyanidin, and 
isoflavone. Most flavonoids exert not only anti-inflammatory and anti-proliferative 
properties but also anti-oxidative activity [4]. Some flavonoids enhance γ-glutamylcysteine 
synthetase (GCSh) expression, increasing intracellular GSH [5], which may in turn improve 
iAs elimination. Dietary micronutrients, such as flavonoids, may modulate iAs elimination; 
however, available information is scarce. A recent study reported an increased intake of the 
soy isoflavones, genistein and daidzein, was associated with decreased urinary percentages 
of iAs and MMA respectively, and an increased percentage of DMA [6]. However, there is 
no information available on the intake of non-soy flavonoids.
Our objective was to evaluate a potential association between selected dietary non-soy 
flavonoids and iAs urinary metabolites in a group of Northern Mexican women exposed to 
iAs in drinking water. We hypothesized that the intake of non-soy flavonoids was positively 
associated with the proportion of DMA in urine.
2. Methods and materials
This cross-sectional study was comprised of 1,027 women that participated from 2007 to 
2009 investigating arsenic exposure in relation to breast cancer risk (Figure 1) [7]. 
Quiller et al. Page 2
Participants were a probabilistic sample of residents living in five states in Northern Mexico. 
Eligibility criteria were ≥ 20 years of age, no history of cancer, and residency period of ≥ 1 
year in the selected states. Women were identified through the master sample framework 
used for the National Health Surveys, from which a probabilistically selected list of housing 
addresses and an access sketch to facilitate their location was obtained [8]. In the houses 
where there was more than one eligible woman, only one participant was randomly chosen. 
Conversely, if no eligible woman was found in a household, or if she declined participation 
in the study, a new home was systematically located according to the standardized survey 
procedures. A grocery incentive was given to controls to increase the response rate.
Pending informed consent, women were interviewed face-to-face by trained interviewers in 
the homes of the women regarding dietary and sociodemographic characteristics. Body mass 
index (BMI) was obtained from anthropometric measurements. The response rate was 99%. 
The project was approved by the Institutional Review Board at the Mexico National Institute 
of Public Health [7].
2.1 Flavonoid intake
The daily consumption of 119 foods and 14 dishes of the previous year was estimated using 
a validated semi-quantitative food frequency questionnaire which included predetermined 
portions for each food, along with 10 response options ranging from "never" to "six or more 
times per day" [9]. Fruit and vegetable frequency of consumption was adjusted according to 
their availability throughout the year. For example, half the reported plum consumption was 
assumed since they are only available six months of the year. Based on the frequency of food 
consumption, we estimated the daily intake of total energy and flavonoids using the United 
States Department of Agriculture nutrient composition tables [10] [11]. For quince and 
Mexican hawthorn, two local foods, we used the tables provided by the Mexico National 
Institute of Nutrition Salvador Zubiran [12].
Food sources of flavonoid included the following fruits: banana, plum, peach, apple, orange, 
blackberry, strawberry, water melon, melon, mango, pear, papaya, fig, pineapple, quince, and 
avocado. In addition, the following vegetables, alliums, legumes, and other food items were 
included: cauliflower, squash flower, broccoli, lettuce, onions, garlic, broad beans, beans, 
green peas, nuts, vegetable oil, coffee, wine, and beer.
We estimated the intake of 21 flavonoids belonging to five groups: anthocyanidins (cyanidin, 
petunidin, delphinidin, malvidin, pelargonidin, and peonidin); flava-3-ols (catechin, 
epigallocatechin, epicatechin, epicatechin 3-gallate, epigallocatechin 3-gallate, and 
gallocatechin); flavanones (eriodictyol, hesperetin, and naringenin); flavones (apigenin and 
luteolin); and flavonols (isorhamnetin, kaempferol, myricetin, and quercetin). Food sources 
of specific compounds are shown in Supplemental Tables S1–S3. Isoflavone consumption 
was not included due to the low dietary intake of soy and its derivatives in the study region.
2.2 Urinary arsenic
Participants donated a first morning void urine sample, not necessarily on the same day of 
interview. Samples were collected in a sterile disposable polypropylene urine collection cup, 
maintained for at least two years at −70 °C until analysis. Concentrations (µg/L) of urinary 
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arsenic metabolite species (iAsIII, iAsV, MMAV, DMAV, and arsenobetaine (AsB)) were 
determined by high performance liquid chromatography ICP-MS system, according to 
methodology previously described [13]. The limit of detection (LOD) for each species was 
iAsIII: 0.15 µg/L; iAsV: 0.41 µg/L; MMAV: 0.12 µg/L; DMAV: 0.12 µg/L; and AsB: 0.08 
µg/L. Measurements below the LOD were given the corresponding concentrations of LOD 
divided by two (LOD/2), as suggested by Barr et al. [14]. The percentages of samples below 
the LOD were iAsIII: 19.28%; iAsV: 56.48%; MMAV: 1.95%; DMAV: 0.49%; and AsB: 
24.15%. The urinary concentration of creatinine (mg/dL) was measured using an enzymatic 
method provided by the Randox kit (Randox, Antrim County, UK). Coefficients of variation 
in duplicate samples were: MMAV= 8%, DMAV= 9%, AsIII= 8% and creatinine= 2.76%.
In order to evaluate urinary iAs, we calculated: 1) iAs concentration from the sum of iAsIII
and iAsV; 2) total arsenic (TAs) as a result of the sum of iAs, MMAV (MMA), DMAV 
(DMA) and AsB; 3) proportions of iAs, MMA and DMA based on the total sum of these; 
and 4) methylation ratios: first= MMA/iAs; second= DMA/MMA; and total= DMA/iAs.
2.3 Statistical analyses
We described sociodemographic characteristics, urinary arsenic metabolite proportions and 
ratios, as well as flavonoid intake using medians, percentiles 10 and 90. Extreme values of 
flavonoid intake were excluded if they exceeded four standard deviations from means. In 
order to assess the relationship between proportions of iAs, MMA, and DMA, as the 
dependent variables and each flavonoid (log transformed) as independent variables, we used 
fractional multinomial logit models (FMLogit). The models use quasi-maximum likelihood 
to evaluate proportions, where each dependent variable is restricted to values between 0 and 
1 and all sum to 1 for each observation [15] We performed sensitivity analyses excluding 
arsenic values below the LOD for each FMLogit model. In addition, we evaluated first, 
second, and total arsenic methylation ratios (log transformed) with multiple linear regression 
models and as a sensitivity analysis we censored arsenic values below the LOD with Tobit 
models [16].
The flavonoid intakes of interest were adjusted for energy, according to the residual method 
proposed by Willett et al. [17]. We considered as co-variables: births (tertile distribution), 
TAs-arsenobetaine (µg/L natural log transformed), BMI (kg/m2 natural log transformed), 
smoking status (non-smokers, ex-smokers, and current smokers), and age (years). To correct 
probability inflation due to multiple statistical modeling we applied a Bonferroni correction 
by considering p-values ≤ 0.002 (0.05/26, 26 = 21 flavonoids + 5 groups) statistically 
significant at a nominal p<0.05. Analyses were performed using Stata 14 (StataCorp, 
College Station, 2015).
3. Results
Participants in the study had medians of: 54 years of age, 6 years of education, 29.95 kg/m2 
BMI, and 48 years of residence in selected states. Half of the women had a reproductive 
profile of 13 years of age at first menstruation, 4 births, 19 years old at first birth, and 36 
months of total breastfeeding among parous (Table 1). Total urinary arsenic, excluding 
arsenobetaine, ranged from 0.57 to 303.29 µg/L (data not shown).
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The weekly median estimated intake of anthocyanidins was the highest amongst groups of 
flavonoids, in contrast to flavones that showed the lowest consumption. Out of 21 
flavonoids, the weekly median consumptions of delphinidin, quercitin, petunidin, and 
hersperitin were the highest; whereas those of pelargonidin, gallocatechin, and eriodictyol 
were the lowest (Table 2).
We found that increases in consumption of the groups of flavan-3-ols and flavones; and 
individually the flavones apigenin and luteolin, as well as the flavanone eriodictyol; were 
significantly associated with increased DMA and reduced iAs proportions. Each 100% 
increase in the consumption of flavan-3-ols, flavones, apigenin, luteolin, and eriodictyol 
decreased (respectively) in 0.0102, 0.0125, 0.0104, 0.0119, and 0.0020 the proportion of 
urinary iAs; and increased in 0.0112, 0.0144, 0.0115, 0.0138, and 0.0026 the proportion of 
DMA, respectively (Table 3).
Total methylation capacity significantly increased by 0.0892 and 0.9888 with each 100% 
increased consumption of the flavan-3-ols and flavones, respectively. Specifically, each 
100% increased consumption of catechin, eriodictyol, apigenin, and luteolin was related to 
an increase in total methylation by 0.0758, 0.0192, 0.0913, and 0.0947 respectively. The 
increased consumption of eriodictyol was also associated with a 0.0121 increased second 
methylation (Table 4).
4. Discussion
We accepted the hypothesis that the intakes of apigenin, luteolin, and eriodictyol non-soy 
flavonoids, as well as the flavan-3-ols and flavones groups, are positively associated with the 
proportion of DMA. These findings are congruent with the Ilmiawati study reporting that the 
consumption of soy-isoflavones increased percentage of DMA and decreased percentages of 
iAs and MMA [6].
The intake of flavan-3-ols, flavanones, flavones, and flavonols in our study sample was 
lower than that reported in two other studies in Europe and the United States of America 
[18,19]. Fruits and vegetables, such as dried oregano, citrus fruits, fresh parsley, fresh 
capers, sorrel, and radish are the main sources of these compounds [20]. Low intake of fruits 
and vegetables in the Northern regions of Mexico has been reported by the National 
Nutrition Survey, confirming our intake estimations [21]. In addition, we found that 
consumption of anthocyanidins is similar to that reported across Europe, but higher than that 
reported in the U.S.A. [18,19]. Food sources of anthocyanidins include grapes, which are 
highly produced in some of the northern states of Mexico [20,22].
Depending on their chemical structure, flavonoids may modulate the activity of GSH. In 
general, those lacking the catechol group in the B-ring show antagonistic behavior with GSH 
intracellular levels; whereas flavonoids with a catechol group, such as quercetin and 
eriodictyol, have opposite actions, as observed in COS-1 kidney and ARPE-19 retinal cells 
[23–25]. Experimentally increased GSH levels in the gastrocnemius muscle were reported in 
mice fed with polyphenol-berries [5].
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In our sample, 17.33 % of women exceeded the occupational health guideline limit of 35 
µg/L of total iAs in urine [26]. It may be possible that even in this highly exposed group, 
flavonoid intake improved iAs elimination since we found an increased proportion of DMA 
after adjusting by total iAs concentration in our statistical analysis. Further studies are 
needed to determine the intake of food sources of flavonoids that would be needed to reduce 
the burden of disease related to iAs exposures.
One limitation of our study was that the assessment of iAs exposure was based on a single 
urine sample, reflecting the metabolic profile of the previous 10 hours [27]. Thus, the 
underlying assumption to interpret our results is that an average water arsenic intake did not 
significantly change on a daily basis over the study period. Additionally, varying dilution of 
urine samples may also distort the results. The concentration of creatinine, an indicator of 
dilution, has been associated with the efficiency of iAs elimination [28]. However, the use of 
creatinine to control for potential concentration/dilution issues is a matter of debate. Some 
authors suggest dividing urinary concentrations of the metabolite of interest by the 
respective concentration of creatinine, whereas others recommend its inclusion as an 
adjustment variable in multivariate models [28,29]. In this study, by using proportions and 
ratios of arsenic metabolites in the present study, the value of creatinine concentration was 
mathematically eliminated. Furthermore, because arsenic concentration was highly 
correlated with several important covariates, it was not included in the final models. Another 
limitation was that due to co-linearity among nutrients related to iAs metabolism, we did not 
include all of them in the models; however, we adjusted our models by confounders 
previously established in the literature [30]. In addition, since this was a secondary analysis 
of a previous study, sample power calculations were not performed.
To reduce differential measurement error, laboratory analyses of urinary arsenic metabolites 
were blinded to the flavonoid intake status; nevertheless, random error should not be ruled 
out and would result in a sub-estimation of our associations. In addition, to reduce the 
possibility of false positive results due to multiple comparisons, we utilized Bonferroni 
adjustment. Furthermore, we performed sensitivity analyses excluding women with iAs 
metabolites below the LOD, which yielded similar results.
In conclusion, our findings suggest that certain non-soy flavonoid intake may improve iAs 
elimination. Nevertheless, there is still very limited information available regarding the 
consumption of flavonoids and iAs metabolism and further research is warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Selection of study population
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Table 1
Characteristics of the study population (n=1027)
Age (years) 54.00 (37.00, 71.00)
BMI (kg/m2) 29.95 (23.44, 38.54)
Education (years) 6.00 (1.00, 11.00)
Residence in the study area (years) 48.00 (30.00, 66.00)
Age at menarche (years) 13.00 (11.00, 15.00)
Parity (number) 4.00 (2.00, 10.00)
Age at first birth (years) 19.00 (16.00, 26.00)
Total breastfeeding (months) † 36.00 (4.00, 158.00)
Cigarettes per day (number) ‡ 4.00 (1.00, 20.00)
Creatinine (mg/dl) 63.99 (18.49, 161.50)
    Arsenic compounds
Total As (µg/g creatinine)§ 25.90 (7.17, 152.94)
Total As-AsB (µg/g creatinine) 19.96 (6.40, 98.41)
  iAs 1.95 (0.63, 9.96)
  MMA 1.82 (0.58, 9.37)
  DMA 15.62 (4.88, 75.22)
AsB 0.85 (0.08, 37.74)
Arsenic proportionsı
iAs 0.10 (0.05, 0.19)
MMA 0.10 (0.06, 0.15)
DMA 0.80 (0.68, 0.87)
    Arsenic ratios
MMA/iAs 1.00 (0.50, 1.79)
DMA/MMA 8.00 (4.52, 14.88)
DMA/iAs 7.84 (3.64, 16.12)
Values are medians, P10 and P90
†Among parous woman
‡Current smokers only
§AsB (µg/g creatinine) in Total As=3.28%
ı
Excluding AsB
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Table 2
Dietary intake of flavonoids (mg/week)
Anthocyanidins 96.31 (30.52, 188.73)
Cyanidin 1.71 (0.36, 6.84)
Petunidin 26.41 (8.71, 61.04)
Delphinidin 40.51 (14.48, 82.27)
Malvidin 18.19 (6.00, 42.03)
Pelargonidin 0.00 (0.00, 4.12)
Peonidin 0.01 (0.00, 0.08)
Flava-3-ols 15.02 (5.68, 45.59)
Catechin 7.35 (1.79, 23.80)
Epigallocatechin 0.63 (0.19, 1.45)
Epicatechin 5.92 (1.14, 14.02)
Epicatechin 3-gallate 0.01 (0.00, 0.07)
Epigallocatechin 3-gallate 0.28 (0.08, 0.80)
Gallocatechin 0.00 (0.00, 0.03)
Flavanones 31.61 (0.77, 169.27)
Eriodictyol 0.00 (0.00, 0.42)
Hesperetin 19.84 (0.00, 110.50)
Naringenin 11.12 (0.77, 61.46)
Flavones 1.84 (0.86, 4.31)
Apigenin 0.06 (0.03, 0.20)
Luteolin 1.75 (0.79, 4.11)
Flavonols 37.14 (21.73, 67.04)
Isorhamnetin 2.90 (0.85, 5.41)
Kaempferol 2.36 (1.27, 5.11)
Myricetin 1.05 (0.49, 1.94)
Quercetin 30.04 (17.78, 56.06)
Values are medians, P10 and P90
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